Inhaled Antibiotics: Negotiating the Obstacles to Treat Mycobacterial Lung Disease
Hofmann T, Banaschewski B, Stapleton KW, Kaiser K, Canisius S, Ufer S.
Respiratory Drug Delivery 2020. Volume 1, 2020: 25-34.
Abstract:
Mycobacterial lung diseases (MLD) are increasingly being recognized as a global health concern. Tuberculosis and nontuberculous mycobacterial pulmonary disease are difficult to treat infections, requiring extensive treatment durations of multiple systemic drugs. These regimens often lead to significant adverse drug events, without necessarily improving bacterial clearance. This review provides an overview of the difficulties in current treatment strategies of MLD, and the potential benefit of inhaled drug delivery in these treatments.
I have a subscription
Log in for instant access.
I do not have a subscription
Purchase Article (in PDF format)
